Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a balanced picture. Financially, the company shows a solid cash position and runway, but faces risks from regulatory changes and market competition. The Q&A reveals positive clinical progress but lacks clarity on timelines, which could concern investors. The $40 million capital raise is a positive, but the absence of specific guidance and potential delays in trials offset this. Overall, the sentiment is neutral as positives are balanced by uncertainties and risks.
Key Financial Performance
Cash and short-term investments $91.7 million, an increase due to the net proceeds from a $40 million capital raise completed in December 2024.
Cash used in operating activities $10.3 million in Q4 2024, consistent with typical quarterly cash burn.
Runway Current cash resources provide runway into the first quarter of 2027, based on cash spend forecasted for ongoing clinical programs.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Onvansertib Efficacy: Patients on the 30 mg dose of onvansertib demonstrated a 64% ORR compared to a 33% ORR in the control arm.
Onvansertib Safety Profile: Onvansertib has a favorable safety profile, differentiating it from previous PLK1 inhibitors that failed due to toxicity.
Market Expansion in mCRC: Cardiff Oncology is focusing on RAS-Mutated Metastatic Colorectal Cancer (mCRC) and plans to complete enrollment of 90 evaluable patients in the CRDF-004 trial in early 2025.
Intellectual Property Strategy: A new patent was issued covering the use of onvansertib in combination with bev for KRAS-mutated mCRC patients, expiring no earlier than 2043.
Financial Position: Cash and short-term investments totaled $91.7 million as of December 31, 2024, providing runway into Q1 2027.
Capital Raise: Successfully completed a $40 million capital raise in December 2024.
Regulatory Strategy: The FDA approval of Pfizer's encorafenib validates Cardiff's registrational strategy for onvansertib in mCRC.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company acknowledges that forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from expectations.
Regulatory risks: The company’s registrational strategy for onvansertib is validated by recent FDA approvals in similar contexts, but any changes in regulatory environment or requirements could pose risks.
Clinical trial enrollment: The company anticipates completing enrollment in the CRDF-004 trial soon, but delays or challenges in patient recruitment could impact timelines.
Intellectual property risks: While the company has strengthened its intellectual property portfolio, there is always a risk of challenges to patents or competition that could affect market position.
Financial risks: The company reported a cash burn of $10.3 million in Q4 2024, and while they have sufficient runway into Q1 2027, any unforeseen expenses could impact financial stability.
Market competition: The competitive landscape in oncology, particularly with other companies like Pfizer achieving regulatory milestones, poses a risk to Cardiff's market position and strategy.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Capital Raise: Successfully completed a $40 million capital raise in December 2024.
Clinical Trial Data: Released initial data from the CRDF-004 trial showing a 64% overall response rate (ORR) for the 30 mg dose of onvansertib compared to 33% in the control arm.
Enrollment Strategy: Expected to complete enrollment of 90 evaluable patients in the CRDF-004 trial in early 2025.
Intellectual Property: Strengthened IP portfolio with a new patent for onvansertib in combination with bev for KRAS-mutated mCRC, expiring no earlier than 2043.
Regulatory Strategy: Validated registrational strategy for onvansertib based on FDA approval pathway used by Pfizer for encorafenib.
Cash Position: Cash and short-term investments totaled $91.7 million as of December 31, 2024.
Cash Burn: Cash used in operating activities was $10.3 million in Q4 2024.
Runway: Current cash resources expected to provide runway into the first quarter of 2027.
Future Data Releases: Expect to release additional clinical data from the CRDF-004 trial in the first half of 2025.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Capital Raise: Successfully completed a $40 million capital raise in December 2024.
Cash and Short-term Investments: As of December 31, 2024, cash and short-term investments totaled $91.7 million.
Cash Used in Operating Activities: Cash used in operating activities was $10.3 million in Q4 2024.
Runway: Current cash resources provide runway into the first quarter of 2027.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you give us any sense of when exactly in the first half that data update is coming and in what context? How many new patients do you expect will become valuable for ORR? How mature do you expect those PFS curves to be?
A:At this point in time, our goal is to give a more mature and substantive update since the 30-patient update. It's probably too early for PFS within the first half of this year, but we will be updating beyond this first half.
Q:Can you just speak to your thoughts around when you will make the dose selection decision and whether that will come together with your interactions with the FDA?
A:Our goal is to get in front of the FDA as soon as possible. We will be discussing the dose (30 vs 20) and finalizing the trial design for the registrational trial 005. This may or may not involve all 90 patients, depending on the signal from the 30 and 20.
Q:Does the response rate delta observed in the BREAKWATER trial align with what you've seen thus far in the 004 study?
A:Yes, their ORR was 61% versus 40%, which is consistent with what we have shown so far with the first 30 patients.
Q:What are your thoughts on the velocity of tumor size reduction and its correlation with approvable endpoints such as PFS and OS?
A:There has been data showing that earlier and deeper responses correlate with greater PFS and OS.
Q:Could the patient number required for accelerated approval in BREAKWATER form the framework for your upcoming discussion with the FDA?
A:We will be talking to the FDA to finalize specifics around our assumptions and trial design, and we are looking at the patient numbers from BREAKWATER.
Q:How do you view the KRAS G12C agent and pan-RAS agents being developed in colorectal cancer?
A:The G12C inhibitors are a small component in colorectal cancer and do not impact our first-line strategy. We are monitoring their progress.
Q:Do you think we'll be able to see all of the 90 patients included in this first half update?
A:Yes, we are very pleased and excited that we're within a couple of weeks of finishing the enrollment.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer regarding the exact timing of the data update and the specifics of how many new patients will be valuable for ORR. Their response about PFS was vague, indicating it is too early for PFS within the first half of the year without providing a clear timeline for future updates.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Antonio Breast
BREAKWATER trial
Breast Cancer
Cancer Symposium
Gilmartin
Group
HR breast
Kiki
ORR
PDX model
San Antonio
agenda
antitumor activity
approval
arm tumor
breast cancer
capital raise
combination
date
dose onvansertib
drug
encorafenib
issuance
mCRC program
mg dose
onvansertib ENHERTU
patent
patient mg
property
registration statement
shelf registration
therapy poster
week
CRDF Transcript
Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript
Unknown2-27
The earnings call presents a balanced picture. Financially, the company shows a solid cash position and runway, but faces risks from regulatory changes and market competition. The Q&A reveals positive clinical progress but lacks clarity on timelines, which could concern investors. The $40 million capital raise is a positive, but the absence of specific guidance and potential delays in trials offset this. Overall, the sentiment is neutral as positives are balanced by uncertainties and risks.
Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript
Unknown8-10
The earnings call summary presents a mixed outlook. Financials show a stable cash position with a runway until Q3 2025, but high cash usage raises financial sustainability concerns. Clinical developments are promising, particularly in mCRC and ovarian cancer, yet regulatory and competitive risks loom large. The Q&A session reveals steady trial enrollment and strategic partnerships, but lacks clarity on scientific validation. Overall, the balance of positive clinical updates and financial/market risks suggests a neutral stock price movement in the near term.
Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript
Unknown5-3
The earnings call presents a mixed outlook. While Cardiff Oncology shows promise with its first-line RAS-mutated mCRC trial and a solid cash runway into Q3 2025, delays in enrollment and reliance on Pfizer Ignite pose risks. The Q&A revealed confidence in trial execution but also highlighted uncertainties, such as the delay in data readouts and lack of diversification into RAS wild-type mCRC. The financial position is stable, but the lack of new revenue streams or shareholder return plans tempers optimism. Overall, the sentiment is neutral, with potential for both positive and negative developments.
Cardiff Oncology, Inc. (CRDF) Q4 2023 Earnings Call Transcript
Unknown3-1
The earnings call indicates a neutral sentiment. While the company has a solid cash runway and a promising partnership with Pfizer Ignite, there are significant risks, including clinical and regulatory challenges, high cash burn, and safety concerns. The Q&A revealed some hesitancy from management to provide detailed responses, which may raise investor concerns. Although there is potential for positive developments, the lack of immediate catalysts and the uncertainties surrounding trial outcomes and market differentiation suggest a neutral stock price movement in the near term.
CRDF Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
